Skip to main content

ASA: Endovascular Thrombectomy Beneficial for Large Ischemic Stroke

Medically reviewed by Carmen Pope, BPharm. Last updated on Feb 16, 2024.

By Elana Gotkine HealthDay Reporter

FRIDAY, Feb. 16, 2024 -- For patients with acute ischemic stroke and large cores, endovascular thrombectomy (EVT) improves clinical outcomes compared with medical management (MM), according to a study published online Feb. 7 in the Journal of the American Medical Association to coincide with the annual American Stroke Association International Stroke Conference, held from Feb. 7 to 9 in Phoenix.

Amrou Sarraj, M.D., from Case Western Reserve University in Cleveland, and colleagues describe the relationship between imaging estimates of irreversibly injured brain and at-risk regions and clinical outcomes and EVT treatment effect in an exploratory analysis of the SELECT2 trial. Adults with acute ischemic stroke due to occlusion of the internal carotid or middle cerebral artery (M1 segment) and large ischemic core were randomly allocated to EVT versus MM across 31 global centers; the analysis included 336 patients.

The researchers found that EVT improved functional outcomes compared with MM in an ordinal analysis of the modified Rankin Scale (mRS) at 90 days within Alberta Stroke Program Early Computed Tomography (CT) Score (ASPECTS) categories of 3, 4, and 5 (adjusted generalized odds ratios [aGenORs], 1.71, 2.01, and 1.85, respectively). The aGenORs for EVT versus MM were 1.63, 1.41, and 1.47, respectively, for ≥70, ≥100, and ≥150 mL across strata for CT perfusion/magnetic resonance imaging (MRI) ischemic core volumes. Outcomes worsened as ASPECTS decreased and as CT perfusion/MRI ischemic volume increased in the EVT group (aGenOR, 0.92 per 10-mL increase).

"EVT improved functional outcomes in ordinal analysis of the mRS score across a wide spectrum of ischemic injury extent when compared with medical management only," the authors write.

Several authors disclosed ties to pharmaceutical and medical device companies, including Stryker; Stryker Neurovascular funded the SELECT2 trial.

Abstract/Full Text (subscription or payment may be required)

Editorial (subscription or payment may be required)

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Read this next

Delay in Hospital Arrival After Stroke Linked to Social Vulnerability

THURSDAY, May 30, 2024 -- Areas with a high incidence of delay in hospital arrival after ischemic stroke are characterized by increased social vulnerability, according to a study...

Infarct Size Does Not Affect Treatment Effect of Early Versus Late DOAC

TUESDAY, May 28, 2024 -- For individuals with minor, moderate, or major stroke, the treatment effect of early versus late direct oral anticoagulant (DOAC) initiation does not...

Extreme Temperatures Linked to Increased Risk for Stroke Death

FRIDAY, May 24, 2024 -- Extreme cold and hot temperatures are associated with an increased risk for death from ischemic and hemorrhagic strokes, according to a study published...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.